October 28 – 29
San Diego, CA
Introduction:
Joe Blanchard
Chief Operating Officer
Aushon BioSystems
Billerica, MA USA
Presenter:
Julia D. Wulfkuhle, Ph.D.
Center for Applied Proteomics and Molecular Medicine
George Mason University
Manassas, VA, USA
Dr. Wulfkuhle received her Ph.D. in Biological Sciences from Purdue University in 1996. She worked as a postdoctoral fellow from 1996-1999 at the Worcester Foundation for Biomedical Research and University of Massachusetts Medical Center and from 1999-2002 in the Laboratory of Pathology/NCI. From 2002-2005 Dr. Wulfkuhle worked as a Research Fellow in NCI/FDA Clinical Proteomics Program and is currently a Research Professor in the Center for Applied Proteomics and Molecular Medicine at George Mason University.
Workshop Abstract
Advances in cancer treatment have generated a need to more precisely define and identify those patients who will derive the most benefit from new-targeted therapeutic agents. Cellular signaling pathways are protein-based networks most often targeted by these drugs, with the intended effect being to disrupt aberrant protein phosphorylation-based signaling activity. The Reverse-Phase Protein Microarray (RPMA) platform has tremendous potential for providing detailed information about the state of the cellular ‘circuitry’ in samples ranging from cell culture lysates to tiny core needle biopsy specimens. When combined with Laser Capture Microdissection (LCM), measurements of hundreds of specific phosphorylated proteins spanning large classes of important signaling pathways can be obtained at once from only a few thousand cells. Implementation of RPMA technology in the preclinical, research and clinical settings for profiling patient tissue specimens before, during and after therapy could provide important diagnostic and prognostic information, and could help in therapeutic decision making and monitoring response or resistance to these new targeted agents.
|
